RUNX1 Familial Platelet Disorder Clinical Trials

Find RUNX1 Familial Platelet Disorder Clinical Trials Near You

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder - Part II

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Other, Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This phase I trial studies the safety and side effects of low-dose sirolimus in treating patients with RUNX1 familial platelet disorder (FPD). RUNX1-FPD is a rare inherited disorder with symptoms such as mild to moderately low platelet count, abnormal platelet function, and an increased risk of developing cancers like myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It is caused by changes (variants) in the RUNX1 gene that is passed down (inherited) from an affected parent. Sirolimus is typically given to help prevent organ rejection in patients receiving kidney transplants. However, sirolimus may also be able to prevent RUNX1-FPD from progressing to cancers like MDS and AML by targeting another protein called mTORC1. Sirolimus may be a safe treatment for patients with RUNX1-FPD.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Patient has provided signed, informed consent before initiation of any study specific procedures

• Aged ≥ 18 years at the time of signing the informed consent

• Confirmed pathogenic/likely pathogenic (P/LP) germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules

• Patient must be willing to provide a bone marrow sample at time of screening and at the end of treatment with sirolimus

• Platelet count of ≥ 50,000/µL

• Creatinine clearance (CrCl) of ≥ 60 mL/min; estimated using the Cockcroft Gault formula or measured by 24 hour urine collection. Exceptions will be allowed, at the discretion of the investigator, for cases of a concomitant medication that alters renal function

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \< 3 × upper limit of normal (ULN)

• Total bilirubin \< 1.5 × ULN

• Left ventricular ejection fraction (EF) \> 50% or at the discretion of the investigator

Locations
United States
Oregon
OHSU Knight Cancer Institute
RECRUITING
Portland
Contact Information
Primary
Knight Cancer Institute Clinical Trials Information
trials@ohsu.edu
503-494-1080
Time Frame
Start Date: 2026-10-05
Estimated Completion Date: 2030-12-31
Participants
Target number of participants: 6
Treatments
Experimental: Treatment (sirolimus)
Patients receive sirolimus PO QD on days 1-168 in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and bone marrow biopsy and/or aspiration throughout the study.
Sponsors
Leads: OHSU Knight Cancer Institute
Collaborators: Oregon Health and Science University, National Cancer Institute (NCI), M.D. Anderson Cancer Center

This content was sourced from clinicaltrials.gov